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delivery of signal 1 (engagement of the T-cell receptor [TCR] with the major histocompatibility complex-peptide complex on antigen-presenting cells) and signal 2 (interaction of costimulatory molecules) is required. 8, 9 However, other players, including innate immunity and inflammation, have been recently recognized to exert a major role. 10, 11 The purine ATP, released during cell damage/inflammation, may serve as 1 such signal. ATP is present at high concentrations within the cells, 12 and it is thus released following cell damage or death 13 ; moreover, ATP can be secreted by immune cells following activation. 14, 15 ATP is abundant at sites of inflammation and is sensed by ionotropic purinergic P2X receptors (7 receptors named P2X1R to P2X7R, or P2XsR). [16] [17] [18] P2XsR have been associated in vitro to T-cell activation and interleukin (IL)-2 production 14, [19] [20] [21] and in vivo to graft-versus-host disease. 18 Recently, ATP has been shown to play a major role in T-helper cell (Th17) differentiation 22 and regulatory T cell (Treg) inhibition, 23 and T-helper cell 1 (Th1) and Th17 immune responses have been associated with organ rejection. 24, 25 Indeed, natural ATP/P2XsR inhibitors with the ability to hydrolyze ATP are expressed on the cellular plasma membrane (eg, the ectonucleotidases CD39 and CD73). 26 Novel P2X7R inhibitors are available for human use, including periodate-oxidized ATP (oATP), CE224,535, AZD9056, and GSK1482160, thereby rendering P2X7R targeting a potential path to be tested in transplantation. 27 oATP, a small Schiff base molecule, is an irreversible antagonist of P2X7R owing to the selective modification of lysine residues that occurs in the vicinity of the ATP-binding site 28 ; oATP has also been proposed to exert additional inhibitory effect on the other purinergic receptors. 20 We aim to unveil the largely unknown role of P2X7R in heart transplantation and to target the ionotropic purinergic receptor P2X7R to achieve tolerance toward cardiac transplants.
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Materials and Methods
Immunologic Methods can be found in the online-only Data Supplement Materials.
Patients
Cardiac samples were obtained from the right side of the interventricular septum of cardiac transplant recipients at Niguarda Ca' Granda Hospital, Milan, Italy. Samples were formalin-fixed, paraffinembedded, sectioned, and histologically graded by a cardiac pathologist according to the 2005 International Society for Heart and Lung Transplantation criteria. 29 Characteristics of patients and the immunosuppressive regimen 30 are depicted in the Table. Mice C57BL/6, BALB/c, C57BL/6 P2X7 −/− , B6.C-H2 bm12 (bm12), and C57BL/6 Rag1 −/− mice of various ages were obtained from the Jackson Laboratory. ABM TCR-Tg mice have been described previously 31 and were maintained as a breeding colony in our animal facility. All mice were cared for and used in accordance with institutional guidelines. Protocols were approved by the Harvard Medical School Animal Care and Use Committee.
Interventional Studies
Mice were injected intraperitoneally with oATP (Medestea srl) 250 µg/d intraperitoneally for 14 days and Colivelin (Tocris, Minneapolis, MN) 7 nmol/L per day for 7 days. In vitro assays were performed in the presence of varying concentrations of oATP, NF-449 (P2X1R inhibitor), and 5-BDBD (P2X4R inhibitor) from Tocris Bioscience (Bristol, UK)
Heart Transplantation
Vascularized cardiac allografts were transplanted intra-abdominally by using microsurgical techniques as described by Corry et al. 32 Rejection was determined as complete cessation of cardiac contractility and was confirmed by direct visualization.
Histology and Immunohistochemistry
Immunohistochemistry was performed with 5-μm-thick formalinfixed, paraffin-embedded tissue section. Photomicrographs (400×) were taken by using an Olympus BX41 microscope (Center Valley, PA). The following primary antibodies were used: anti-Mac2, anti-CD3 (Cell Marque, CA), anti-CD20, anti CD68 (Dako, Glostrup, Denmark), and anti-P2X7 (Alomone Labs, Jerusalem, Israel). As isotype control for anti-P2X7R, normal rabbit immunoglobulin G (R&D Systems, MN) was used. Graft histology was evaluated by an expert pathologist and was quantified as follows: (i) heart coronary vasculopathy: 0, normal arteries; 1, mild arterial wall infiltration; 2, heavy arterial wall infiltration with partial luminal occlusion; 3, complete luminal occlusion; and (ii) heart cell infiltrate: 0, no cell infiltrate; 1, mild cell infiltrate; 2, medium cell infiltrate; 3, heavy cell infiltrate. 
Confocal Microscopy
Immunofluorescence samples were observed by using a confocal system (LSM 510 Meta scan head integrated with the Axiovert 200 mol/L inverted microscope; Carl Zeiss, Jena, Germany) with a 63× oil objective. Images were acquired in multitrack mode with the use of consecutive and independent optical pathways.
Quantitative Real-Time Polymerase Chain Reaction
RNA was purified by using an RNeasy kit (Qiagen, CA) and was reverse-transcribed into cDNA by using Superscript III (Invitrogen, CA). Transcripts were amplified using a 7300 Real-Time polymerase chain reaction (PCR) System (Applied Biosystems, CA); primers were obtained from Applied Biosystems. Real-time PCR products were normalized to copies of GAPDH.
Flow Cytometry and Intracellular Cytokine Staining
Annexin V Apoptosis Detection Kit, anti-mouse CD4, CD8, CD25, CD44, CD62L, interferon-γ (IFN-γ), IL-17, and FoxP3, were purchased from BD Biosciences and eBioscience (San Diego, CA), antimouse P2X7 was purchased from Alomone Labs.
33
Phoshoprotein Determination
Cells were lysed by using 30 µL of lysis buffer provided with the Millipore MILLIPLEX MAP kit (Millipore, MA) supplemented with protease inhibitor. The Millipore MILLIPLEX MAP Cell Signaling Assay and the Luminex xMAP platform were used according to the manufacturer's protocol (Millipore).
Western Blot
Total protein concentration in cell lysates was measured by using a Bradford assay (Bio-rad, CA). Proteins were resolved on an sodium dodecyl sulfate polyacrylamide gel via electrophoresis and were transferred to a nitrocellulose membrane and then incubated with primary rabbit anti-P2X1, anti-P2X4, and anti-P2X7 receptor antibodies (Alomone Labs), anti-T-bet/Tbx21 and anti-ROR-γ (Abcam, MA), anti-Stat3 and anti-Phospho Stat3 (Ser727) (Cell Signaling, MA), and GAPDH (Cell Signaling), as well. Densitometric quantification of band intensity was analyzed by using ImageJ software and was normalized to GAPDH-loading control expression.
Statistical Analysis
Data are expressed as means±standard error of mean. Statistical differences in survival times were determined by the use of KaplanMeier curves, followed by the log-rank test. Analyses were performed in SAS (SAS Institute, NC, v. 9.3). All data were transformed to their base 10 logarithms for their statistical evaluation. The Levene test was used to test homogeneity of variances. Whenever unequal variances existed in the comparison of 3 groups or more, Welch analysis of variance with appropriate degrees of freedom (≥2) was used to compare the groups. Subsequently, post hoc analysis of Welch t test with Bonferroni correction was applied. In the 2-group comparison, Levene test and Welch t test were used. P<0.05 was considered significant. Graphs were generated by using GraphPad Prism version 5.0 (GraphPad Software).
Results
P2X7R Is Induced in Cardiac Transplants During the Alloimmune Response
We evaluated the expression of P2XsR in cardiac transplants in vivo. Hearts from BALB/c (H-2 d ) mice were heterotopically transplanted into C57BL/6 (H-2 b ) mice, and cardiac transplants and splenocytes were harvested at day 7 after transplantation (the average time for cardiac transplant rejection). Expression of the P2XsR was compared with baseline values (ie, untransplanted BALB/c hearts or naïve C57BL/6 splenocytes) by real-time PCR. Upregulation of P2X1R (14-fold increase), P2X4R (4-fold increase), and P2X7R (9-fold increase) receptors was observed in the cardiac transplants ( Figure 1A , 1D, and 1G). Conversely, no induction of P2XsR was observed in splenocytes of cardiac-transplanted mice (data not shown). To dissect the specific effect of the alloimmune response from effects of ischemia-reperfusion injury and nonspecific inflammation, we compared P2XsR expression in allografts and syngrafts (C57BL/6 hearts into C57BL/6 recipients). P2X1R, P2X4R, and P2X7R were also upregulated in syngeneic heart transplants in comparison with baseline ( Figure 1A , 1D, and 1G); however, only P2X7R was significantly increased in allogeneic in comparison with syngeneic transplants ( Figure 1G ). P2X2R, P2X3R, P2X5R, and P2X6R ( Figure 1B, 1C, 1E , and 1F) expression was unchanged in both cardiac syngrafts and allografts in comparison with baseline. We then assessed which cell type was responsible for the P2X7R upregulation observed with the use of immunohistochemical analysis. P2X7R staining was negative in untransplanted BALB/c hearts (data not shown), whereas clear positive staining was evident in the mononuclear immune cell infiltrate of cardiac transplants harvested at day 7 ( Figure 1H1 and 1H2) ; cardiomyocytes and other parenchymal cells appeared to be negative for P2X7R staining. We also confirmed complete overlap between CD3 + T cells and P2X7R expression via immunofluorescence and confocal microscopy ( Figure 1I1 through  1I3 ). In addition, we evaluated whether P2X7R upregulation was a phenomenon present in patients (Table) . When we analyzed the graft infiltrate in patients experiencing acute heart rejection, clear expression of P2X7R was observed ( Figure  1J1 and 1J2), and confocal imaging confirmed that P2X7R staining overlapped with CD3 staining (Figure 1K1 In Vivo Short-term P2X7R Targeting Prevents Cardiac Transplant Rejection, Abrogates the Th1/ Th17 Immune Response, and Reduces Effector T
Cells in Mice
We next tested the effect of P2X7R targeting in preventing cardiac transplant rejection by using the P2X7R inhibitor oATP. Untreated C57BL/6 mice transplanted with BALB/c hearts (fully mismatched) invariably rejected grafts within 7 days (mean survival time of 7 days; Figure 2A ). P2X7R targeting with the use of the short-term treatment of oATP (250 mg oATP intraperitoneally daily for 14 days) induced long-term cardiac transplant survival (>100 days) in 80% of recipients ( Figure 2A) . To evaluate the effect of P2X7R targeting on the immune system of cardiac-transplanted mice, splenocytes were harvested at days 7 and 100 posttransplantation and were challenged with BALB/cirradiated splenocytes in an enzyme-linked immunosorbent spot (ELISPOT) assay. Reduced numbers of IFN-γ-producing cells ( Figure 2B ) and increased numbers of IL-4-producing cells ( Figure 2C ) were observed in oATP-treated in comparison with untreated mice at day 7; a stronger effect was observed at day 100 in oATP-treated mice ( Figure 2B and 2C). Figure 2D ) and CD8 + Teffs ( Figure 2E ) were reduced by in vivo short-term P2X7R targeting in mice at days 7 and 100 posttransplantation in comparison with untreated mice. The percentage of Th17 cells was similarly reduced ( Figure  2F ). No differences in the percentage of Tregs were observed between treated and untreated mice at day 7, but an increase was observed at day 100 ( Figure 2G ). Thus, we show that short-term P2X7R targeting reshapes the immune system and induces hyporesponsiveness toward donor antigens.
In Vivo Short-term P2X7R Targeting Induces Anergy Toward Donor-Derived Alloantigens but Preserves Immunocompetence in CardiacTransplanted Mice
To assess whether long-term cardiac transplant survival was associated with active regulation toward alloantigens or with reduced immunocompetence, hearts from BALB/c mice were transplanted into immunodeficient C57BL/6 Rag −/− mice together with splenocytes obtained from cardiac transplant recipients. Graft rejection was observed within 20 days in mice adoptively transferred with naïve C57BL/6 splenocytes, and no protection was observed when splenocytes obtained from mice with long-term graft function were coadoptively transferred with naïve splenocytes ( Figure 2H ). Conversely, prolonged graft survival >50 days was observed when splenocytes obtained from cardiac-transplanted mice with long-term Figure 1 . Syngeneic C57BL/6 (Syngeneic Tx) and allogeneic BALB/c cardiac transplants (Allogeneic Tx) were harvested from C57BL/6 recipient mice 7 days posttransplantation, and P2XsR mRNA levels were compared with untransplanted BALB/c hearts (Baseline). An upregulation of P2X1R (A), P2X4R (D), and P2X7R (G) expression in both syngrafts and allografts was evident in comparison with baseline (n=3, *P<0.05, **P<0.01); greater P2X7R upregulation was observed in allogeneic than in syngeneic heart transplants (n=3, #P<0.05; G). No upregulation for P2X2R (B), P2X3R (C), P2X5R (E), and P2X6R (F) was observed. Substantial infiltration was observed at day 7 after transplantation in allografts (H1). Immunohistochemistry revealed that mononuclear infiltrating cells were positive for P2X7R expression (H2), whereas myocytes, endothelial cells, and fibroblast showed no expression (H2). Immunofluorescence confirmed complete overlapping between CD3 + T cells and P2X7R expression (I1 through I3). P2X7R was expressed in lymphocytes infiltrating human cardiac transplants undergoing acute rejection as well (J1 and J2). Complete overlapping between CD3 + T cells and P2X7R was also demonstrated (K1 through K3), whereas no colocalization was observed between P2X7R (red; L and M) and CD20 + B cells (green, L) or CD68 + macrophages (green, M). P2X1R indicates purinergic receptor P2X1; P2X2R, purinergic receptor P2X2; P2X3R, purinergic receptor P2X3; P2X4R, purinergic receptor P2X4; P2X5R, purinergic receptor P2X5; P2X6R, purinergic receptor P2X6; P2X7R, purinergic receptor P2X7; and H&E, hematoxylin and eosin.
at UniversitÃ degli Studi di Milano on June 24, 2014 http://circ.ahajournals.org/ Downloaded from graft function were adoptively transferred ( Figure 2H ). These data suggest that in vivo short-term P2X7R targeting is more likely to induce anergy toward graft antigens than to induce active regulation. We then tested the immunocompetence of treated mice at day 100 after transplantation. Naïve C57BL/6 mice or oATP-treated mice were immunized with ovalbumin, and splenocytes were rechallenged in vitro 7 days later; no differences in numbers of IFN-γ-producing cells were observed ( Figure 2I ). These data demonstrate that in vivo short-term P2X7R targeting promotes anergy toward graft antigens while maintaining immunocompetence.
In Vivo Short-term P2X7R Targeting Reduces Infiltration and Th1/Th17 Transcripts in Cardiac Transplants
To further investigate the effect of in vivo short-term P2X7R targeting on the antigraft response, we analyzed cardiac transplant infiltrate in oATP-treated and untreated mice. Histological analysis performed at day 7 posttransplantation revealed a reduced CD3 + T cell infiltrate in treated ( Figure 3B1 and 3B2) in comparison with untreated mice ( Figure 3A1 and 3A2), and semiquantitative analysis confirmed a reduction in degree of infiltration and of coronary vasculopathy ( Figure  3C and 3D). To investigate the effect of oATP treatment on Th1 and Th17 cells infiltrating the cardiac transplant, we analyzed allograft mRNA expression of T-bet (a Th1 cell marker) and of ROR-γ (a Th17 cell marker); both markers appeared substantially reduced in oATP-treated mice ( Figure  3E and 3F), but no difference in the Th2 transcript GATA3 was observed (data not shown). At day 100, cardiac allografts were well preserved and free from infiltration in oATP-treated mice ( Figure 3G1 and 3G2) . Thus, pathological analysis confirms that P2X7R targeting preserves cardiac transplant morphology. P2X7R inhibition with oATP in the BALB/c into C57BL/6 cardiac transplantation model prevented transplant rejection in 80% of transplants (n=15, ***P<0.001 versus Untreated; A). When recipient splenocytes were rechallenged with donor splenocytes in an ELISPOT assay at day 7 after transplantation, they displayed fewer IFN-γ-producing cells (n=5, ***P<0.001 versus Untreated day 7; B) and more IL-4-producing cells (n=5, ***P<0.001 versus Untreated day 7; C) with further polarization at day 100 (n=5, IFN-γ: ###P<0.001; IL-4: #P<0.05 versus Untreated and oATP-treated day 7; B and C). A significant reduction in the number of CD4 + Teffs (n=5, *P<0.05, **P<0.01 versus Untreated day 7; D), CD8 + Teffs (n=5, ***P<0.001 versus Untreated day 7; E), and IL-17 + CD4 + T cells (n=5, *P<0.05 versus Untreated day 7; F) was observed at days 7 and 100 in oATP-treated mice. No differences in the percentages of peripheral Tregs were observed between oATP-treated and untreated mice at day 7, whereas an increase in the Treg population was seen at day 100 (n=5, ***P<0.001 versus Untreated day 7, ###P<0.001 versus oATP-treated day 7; G). BALB/c cardiac transplant rejection was observed in C57BL/6 Rag −/− mice adoptively transferred with naïve C57BL/6 splenocytes alone (Controls) or in combination with splenocytes from oATP-treated mice, whereas prolonged graft survival was observed when splenocytes from oATP-treated mice were transferred alone (n=4, ***P<0.001 versus Controls; H). Immunocompetence was preserved in oATP-treated mice as assessed by in vitro ovalbumin response after in vivo immunization (n=3, ***P<0.001 versus Unimmunized; I). ELISPOT indicates enzyme-linked immunosorbent spot; IFN-γ, interferon γ; oATP, periodate-oxidized ATP; IL-4, interleukin 4; and IL-17, interleukin 17. January 29, 2013
In Vivo Short-term P2X7R Targeting Inhibits the Expansion of Alloantigen-specific T Cells
To address whether the inhibition of the effector T-cell compartment is related to reduced priming and expansion of alloreactive T cells or to their increased apoptosis, we tracked alloreactive-specific T cells in a transgenic model of cardiac transplantation. Bm12 hearts were transplanted into C57BL/6 Rag −/− mice, and 3 × 10 6 ABM CD4 + TCR-Tg T cells (specific for bm12 major histocompatibility complex class II antigens) were subsequently adoptively transferred into cardiac transplant recipients. 31 Seven days posttransplantation, reduced numbers of ABM CD4 + TCR-Tg T cells were evident in oATP-treated in comparison with untreated mice ( Figure  4A ). A marked reduction in the numbers of Teffs and Th17 cells within the Tg population was also observed in oATPtreated in comparison with untreated mice ( Figure 4B and 4C, respectively). We then examined whether the reduced number of alloantigen-specific CD4 + T cells was due to reduced proliferation or to increased apoptosis. A decrease in ABM CD4 + TCR-Tg T-cell proliferation, as assessed by the dilution of the intracellular dye carboxyfluorescein diacetate succinimidyl ester, was observed in oATP-treated ( Figure 4E ) in comparison with untreated mice (Figure 4D ), without substantial differences in TCR-Tg T-cell apoptosis 4 days following adoptive transfer ( Figure 4F and 4G) . The results obtained demonstrate that the inhibition of the effector cell compartment on oATP treatment is not mediated by a significant increase in apoptosis, but rather by decreased proliferation.
P2X7R is Required for oATP to Prolong Cardiac Transplant Survival
oATP has been proposed to exert secondary immunomodulatory mechanisms, primarily related to the inhibition of the remaining P2XsR. 20 To verify that the effect on the prevention of cardiac transplant rejection was predominantly due to P2X7R inhibition, we made use of the P2X7R −/− C57BL/6 mouse model. BALB/c hearts were transplanted into P2X7R −/− mice, and cardiac transplant survival was compared with that of wild-type recipients. A significant prolongation of cardiac transplant survival was observed in P2X7R −/− recipients, confirming the role of P2X7R in allograft rejection (Figure 5A) . The ability of oATP to prolong cardiac transplant survival was severely altered in P2X7R −/− mice, suggesting that, in the context of cardiac alloimmune response, oATP acts mainly, although not exclusively, through P2X7R (Figure 5A) . Moreover, these data suggest that compensatory mechanisms exist in P2X7R −/− mice; indeed, ATP has been shown to signal through other P2XsR, in particular, through P2X1R and P2X4R in the context of T-cell activation and immune function. 21 We thus analyzed CD4 + T cells obtained from P2X7R −/− mice by Western blot, and an upregulation of P2X1R and P2X4R was observed in comparison with wild-type mice ( Figure 5B through 5D ). Given these data, Figure 5E and 5F, respectively), thus demonstrating that genetic deletion of P2X7R and the compensatory upregulation of other P2XsR exert profound and complex effects on T-cell activation and homeostasis. 
T-Cell Activation and Th1/Th17 Differentiation
To address the mechanisms underlying P2X7R targetingmediated inhibition of cardiac transplant rejection, we analyzed the effect of P2X7R targeting on T-cell activation and Th1/Th17 differentiation in vitro. P2X7R was expressed on CD4 + and CD8 + T cells isolated from splenocytes, as assessed by Western blotting and real-time PCR, with higher expression levels observed in CD4 + T cells ( Figure  6A and 6B) . We then tested the effect of in vitro P2X7R targeting with oATP during CD4 + T-cell activation. First, in an ELISPOT assay, naïve CD4 + T cells were stimulated with 0.5 µg/mL anti-CD3-Ig and anti-CD28-Ig for 24 hours, and, when 100 µM oATP was added to cultures, the number of IFN-γ-producing CD4 + T cells was significantly reduced in comparison with controls ( Figure 6C) . Second, in a T-cell proliferation assay, carboxyfluorescein diacetate succinimidyl ester-labeled naïve CD4 + T cells were stimulated for 96 hours with 0.5 µg/mL anti-CD3-Ig and anti-CD28-Ig, and treatment with 100 µM oATP diminished CD4 + T cell proliferation ( Figure 6D , lower) in comparison with controls ( Figure 6D , upper). Expression levels of the P2XsR were not influenced by the presence of oATP during anti-CD3-Ig/anti-CD28-Ig stimulation (online-only Data Supplement Figure IA) . To assess whether oATP is specific for P2X7R or whether it also induces its effect through the inhibition of other purinergic receptors (eg, P2X1R or P2X4R, which have been involved in immune function), 21 we combined 100 µM oATP with 50 µM P2X1R (NF-449) and 50µM P2X4R (5-BDBD) inhibitors; a further suppression of anti-CD3-Ig/anti-CD28-Ig-mediated IFN-γ production was obtained ( Figure 6E ). These data demonstrate that the concentration of oATP is not (at least not completely) blocking P2X1R and P2X4R. We next tested the effect of in vitro P2X7R targeting during a Th1/Th17 generation and differentiation assay. 
In Vitro and In Vivo P2X7R Targeting Inhibits STAT3 Phosphorylation
We next assessed which molecular pathway during T-cell activation was preferentially inhibited by the targeting of P2X7R. Several key components of T-cell receptor signaling involved in the alloimmune response 34 were examined, and the phosphorylation kinetics following in vitro anti-CD3-Ig/anti-CD28-Ig-mediated CD4 + T-cell activation was evaluated by using the Luminex assay. 35 Peak phosphorylation for the analyzed pathways was observed at 30 minutes for JNK/SAPK1 and at 60 minutes for p70/S6, STAT3, and STAT5; a second peak was seen for STAT5 at 24 hours ( Figure 7A) . A significant inhibition of activation-induced STAT3 phosphorylation was observed when oATP was added to the culture ( Figure  7E ), whereas the phosphorylation of JNK/SAPK1, p70/S6, or STAT5 in CD4 + T cells was unaffected ( Figure 7B through 7D, respectively). We then confirmed by Western blot that oATP dose-dependently inhibits STAT3 phosphorylation ( Figure 7F ). To demonstrate that the effect of oATP is STAT3-phosphorylation-inhibition dependent, we tested the effect of Colivelin treatment, a peptide that promotes STAT3 phosphorylation 36, 37 in an add-back experiment. We first confirmed that Colivelin (Col) was able to restore the activation-induced phosphorylation of STAT3 in a dose-dependent manner in oATP-treated CD4 + T cells by Western blotting ( Figure 7G ). Moreover, in an ELISPOT assay, in which naïve CD4 + T cells were stimulated with 0.5 µg/mL anti-CD3-Ig and anti-CD28-Ig, treatment with Colivelin was shown to significantly revert oATP-mediated suppression of IFN-γ-producing cells ( Figure 7H ). The effect of oATP and Colivelin on STAT3 phosphorylation and T-cell function was also evaluated following cardiac transplantation. BALB/c hearts were transplanted into C57BL/6 mice, and STAT3 phosphorylation was assessed by Western blot in CD4 + T cells isolated from splenocytes of mice 7 days after transplantation. oATP-treated mice displayed reduced levels of phosphorylated STAT3 in comparison with untreated mice, and, paralleling the results obtained in vitro, the use of Colivelin was able to reestablish STAT3 phosphorylation in CD4 + T cells of oATP-treated mice ( Figure 7I and 7J) . From a functional point of view, the use of Colivelin greatly abrogated the effect of oATP on allograft survival ( Figure 7K ). These data demonstrate that P2X7R signaling is crucial for T-cell activation and Th1/Th17 generation and that this effect is STAT3 dependent.
In Vivo Short-term P2X7R Targeting Prevents Coronary Vasculopathy in a Model of Chronic Heart Cardiac Transplant Rejection
To evaluate the importance of P2X7R signaling and targeting in a clinically relevant setting, we tested the effect of oATP treatment in a model of cardiac transplant chronic rejection (bm12 donors to C57BL/6 recipients). In this model, C57BL/6 mice do not acutely reject bm12 cardiac allografts, but transplanted hearts develop transplant-associated coronary vasculopathy. Cardiac allograft pathology was assessed 40 days after transplantation of bm12 hearts into C57BL/6 mice. Advanced coronary vasculopathy and severe lymphocyte and macrophage interstitial and vascular infiltration were observed in untreated mice ( Figure 8A1 through 8A4) in comparison with oATPtreated mice ( Figure 8B1 through 8B4) , which displayed only mild cellular infiltration and the absence of coronaropathy, as well ( Figure 8C and 8D, respectively) . oATP-treated mice also showed a reduced number of IFN-γ-producing cells ( Figure  8E ) and an increased number of IL-4-producing cells ( Figure  8F ) in an ELISPOT assay when splenocytes were challenged with donor antigens.
Discussion
The introduction of novel immunosuppressive drugs has led to significant improvement in short-term cardiac transplant survival rates but has been unable to significantly improve allograft survival in the long-term 1,2 Furthermore, current immunosuppressive regimens are associated with multiple complications, including cancer, opportunistic infections, diabetes mellitus, kidney failure, and hypertension. [2] [3] [4] To improve transplantation outcomes, it is therefore critical to continue the development of novel strategies to lessen the need for lifelong immunosuppression and to achieve stable graft acceptance. We thus studied the role of the ionotropic purinergic P2X receptors (a family of receptors with largely unknown function in the alloimmune response) in cardiac transplant rejection and tolerance.
Aside from signal 1 (TCR engagement) and signal 2 (costimulatory molecule interaction), soluble signals have also been recognized as major players in T-cell activation; we predicted that ATP would exert a fundamental role in the context of allograft organ rejection, in particular, in the first phase after transplantation when it could be released in marked amounts by necrotic or ischemic cells. Among all P2XsR, our data show that P2X7R is specifically upregulated during the alloantigen response in the graft and is expressed by virtually all T cells infiltrating the graft. On the contrary, P2X1R and P2X4R are similarly increased in both syngrafts and allografts, and their upregulation may thus be more related to ischemia reperfusion injury and to posttransplant inflammation than specifically to the alloantigen response. It is noteworthy that we found P2X7R to be upregulated in T cells infiltrating cardiac transplants during clinical acute rejection, confirming the relevance of the P2X7R pathway in patients undergoing heart transplantation. In vivo, short-term P2X7R targeting with oATP robustly promoted long-term cardiac transplant survival in 80% of the recipients in a fully mismatched model of heart transplantation; moreover, oATP was able to inhibit the development of coronary vasculopathy in a chronic model of cardiac rejection. oATP was initially and primarily described as a P2X7R inhibitor, 28 and, although recent articles have pointed to a broader effect of oATP as an inhibitor of other purinergic receptors, 20 oATP remains to date the most well-characterized and effective drug to target in vivo P2X7R. 38, 39 The relative ineffectiveness of oATP treatment in P2X7R −/− mice appears to confirm that, although additional inhibition of other purinergic receptor may be present, there is a more restricted P2X7R-mediated effect in our model; moreover, our in vitro data show that, at the concentration used, oATP does not (at least not completely) inhibit other P2XsR. P2X7R targeting is associated with a reduction in Teff and Th17 cells, which are known to be highly relevant to the alloimmune response, and we observed a reduction in the Th1/Th17 lymphocytic infiltrate. Inhibition of the antigraft effector T-cell compartment (Th1 and Th17) may thus be responsible for the observed long-term graft function. Although P2X7R inhibition has been related to a Th17-toTreg shift in in vitro assays 23 and in a model of inflammatory bowel disease, 14 flow cytometric analysis of treated mice does not support a clear expansion of the Treg compartment (observed only later after treatment) in our model. In contrast, our adoptive transfer experiments show an inhibition of the antigraft effector T-cell compartment and demonstrate, as well, a state of anergy toward graft antigens in treated mice, which is likely responsible for the observed long-term graft survival. Anergy toward alloantigens does not seem to be related to a state of chronic immunosuppression, as demonstrated by the preserved anti-ovalbumin response after immunization, which is particularly applicable to the clinical setting. From a molecular point of view, targeting P2X7R appears to be a result of activation-mediated STAT3 phosphorylation, given the reduced level of phosphorylated STAT3 following oATP treatment. Furthermore, Colivelin treatment, which restores STAT3 phosphorylation, reverts, although not completely, the effect of in vitro and in vivo oATP treatment, showing that other pathways may be affected by oATP. 14, 18 STAT3 is a wellknown transcription factor with multiple roles in mediating T-cell activation and proliferation. 22, 40, 41 Our in vitro and in vivo data point to a novel axis in T-cell activation, which links ATP-P2X7R-STAT3 and activation of the antigraft effector T-cell compartment (Th1 and Th17 cells), which can be inhibited by the use of oATP. The centrality of this pathway at the crossroads of T-cell activation and differentiation is further demonstrated by the transduction of P2X7R on T cells and the associated effects of greater activation and Th1/ Th17 differentiation. The P2X7R pathway in T cells is highly important in the context of cardiac transplant rejection and may synergize with the P2X7R pathway in antigen-presenting cells 18 to promote graft rejection. Willhem and colleagues have recently described a role for P2X7R in graft-versus-host disease 18 by using the P2X7R −/− model; in comparison, (i) we tested a pharmacological inhibitor of P2X7R, which is more clinically relevant; (ii) we tested the effect of P2X7R targeting in 2 different models of solid-organ transplantation (ie, the acute and the chronic rejection model); (iii) we demonstrated a direct effect of P2X7R inhibition on T cells, which is independent of the inhibitory effect on antigen-presenting cell function; (iv) we showed that the effect of P2X7R targeting is mediated by an inhibition of the T-cell effector compartment more than by an expansion of the regulatory T-cell compartment; (v) we highlight the necessity of exercising some caution in the analysis of data by using P2X7R −/− mice given that the upregulation of other P2XsR (in the knock-out mouse, but not during pharmacological targeting) may partially obscure P2X7R function. On the NIH clinical trials web site (http:// www.clinicaltrials.gov), nearly 80 clinical trials are registered to promote tolerance in transplantation. None of these trials is specifically aimed or designed to target P2X7R-mediated alloimmunity, yet our results clearly indicate the need for novel therapeutic options for transplantation. We envision P2X7R-mediated immunity as a novel pathway for cardiac transplant rejection. Indeed, a P2XR-targeting strategy has considerable translational potential, because novel anti-P2X7R inhibitors are available for clinical use (eg, oATP, CE 224,535, AZD9056, and GSK1482160). Short-term P2X7R targeting at the time of transplantation may prove to be valuable in the clinical setting by promoting cardiac transplant acceptance, lessening the need for chronic immunosuppression, and preventing the development of coronary graft vasculopathy.
CLINICAL PERSPECTIVE
Heart transplantation is a lifesaving procedure for patients with end-stage heart failure and provides a better survival and quality of life in comparison with medical treatment or device-based therapies. Recently, advances in immunosuppression and improved clinical care have enhanced the early survival of patients with cardiac transplants. However, >20% of patients do not survive beyond 3 years, and those who survive are afflicted with the long-term complications associated with chronic immunosuppression (eg, posttransplant diabetes mellitus, coronary vasculopathy, nephropathy, infections, and malignancies). To improve transplantation outcomes and lessen the need for life-long immunosuppression, it is crucial to continue the development of novel immunomodulatory strategies. Short-term targeting of the purinergic receptor P2X7 (P2X7R) may provide a novel therapeutic opportunity. Soon after transplantation, purine ATP is released by necrotic cells and causes the activation of graft-infiltrating T cells, which sense ATP by the highly expressed receptor P2X7R. Our data show that shortterm P2X7R targeting with periodate-oxidized ATP robustly promotes, in a fully-mismatched model of acute rejection, long-term cardiac transplant survival in 80% of recipients, with preservation of immunocompetence. Moreover, periodateoxidized ATP inhibits the development of coronary vasculopathy in a model of chronic rejection. Nearly 80 clinical trials are registered on the National Institutes of Health web site to promote long-term graft function, and none of these is designed to target P2X7R-mediated alloimmunity. Because novel P2X7R inhibitors are available for clinical use (eg, periodate-oxidized ATP, CE-224,535, AZD9056, and GSK1482160), short-term P2X7R targeting may have considerable translational potential by promoting cardiac transplant acceptance, thereby lessening the need for chronic immunosuppression and preventing the development of coronary vasculopathy. Cell purification and CFSE labeling CD4 + , CD8 + , and CD4 + CD25 -T cells were isolated from splenocytes using MACS microbeads (Miltenyi Biotec, Auburn, CA). CFSE labeling was performed using the Vybrant® CFDA SE Cell Tracer Kit (Invitrogen, Carlsbad, CA).
ELISPOT
An ELISPOT assay was used to measure the number of IFN-γ-/IL-4-producing cells (BD Biosciences, San Jose, CA). Allogeneic splenocytes (BALB/c) or anti-CD3-and anti-CD28-Ig (BD Biosciences, 0.5 µg/ml each) were used to stimulate 1x10 6 responder splenocytes or 2x10 5 T cells (C57BL/6) 1 . Spots were counted using an Immunospot analyzer (Cellular Technology Ltd., Cleveland, OH). In a similar experiment, expression levels of P2XsR were assessed by quantitative real-time PCR.
Ovalbumin immunization
Ovalbumin peptide (Sigma Aldrich, St. Louis, MO) emulsified in complete Freund's adjuvant (Sigma Aldrich) was injected once (100 µg/mouse i.p.). Splenocytes were collected and used in in vitro assays after rechallenge with 1 µmol/L ovalbumin peptide for 24 h 2 .
T-cell differentiation assay
Naive sorted CD4 + CD25 -T cells (Th0) were isolated and activated for 5 days with 1 µg/ml of plate-bound anti-CD3 and anti-CD28 antibodies (BD Biosciences). Cultures were supplemented with either 5 ng/ml mIFN-γ and 10 µg/ml of anti-IL-4 mAb for Th1 differentiation, or with 10 µg/ml of anti-IFN-γ mAb and anti-IL-4 mAb, 5 ng/ml of mTGF-β and 20 ng/ml of rIL-6 for Th17 differentiation. Proteins and antibodies were purchased from R&D Systems (Minneapolis, MN) and BD Biosciences.
P2X7R transfection of T cells
The hP2X7R 
